Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1

Status

Terminated 2Completed 2

Sponsor Class

OTHER 4INDUSTRY 3

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Dermatologic 1

Conditions

Urinary Bladder Neoplasms 3Melanoma 1Carcinoma, Transitional Cell 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Has results × BCG Vaccine × Clear all
NCT00070070 2022-10-12

Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas

Ludwig Institute for Cancer Research

Phase 1 Completed
6 enrolled 7 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01838200 2022-10-12

Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1 Terminated
5 enrolled 12 charts
Dermatologic

Melanoma

NCT01373294 2019-08-06

Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
17 enrolled 8 charts
Genitourinary

Urinary Bladder Neoplasms

NCT00974818 2015-11-20

Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients

Memorial Sloan Kettering Cancer Center

Phase 3 Terminated
50 enrolled 7 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡